Announcements
Subscribe to RSS:
-
Now open: Broad Agency Announcements
Now open: Broad Agency Announcements for Advanced Research and Development of Medical Countermeasures for Pandemic Influenza and Chemical, Biological, Radiological and Nuclear Threats...
2012
2011
- First U.S. cell-based flu vaccine plant set for dedication [December 2011]
The first U.S. facility to use a faster and more flexible technology to make influenza vaccine was dedicated today, as part of an initiative that could provide vaccine supplies sooner in an influenza pandemic
- BARDA Strategic Plan 2011-2016 Released [October 2011]
BARDA develops and procures needed MCMs, including vaccines, therapeutics, diagnostics, and non-pharmaceutical countermeasures, against a broad array of public health threats, whether natural or intentional in origin
- BARDA Supports Development of Drugs to Treat Chemical Injury [September 2011]
Two contracts for advanced research and development of drugs to treat injury from exposure to deadly chemical agents were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
- BARDA partners to develop new class of antibiotic [September 2011]
The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization
- Novel anthrax vaccine and antitoxin being developed with federal support [September 2011]
The advanced development of a novel next-generation anthrax vaccine and a new type of anthrax antitoxin have received support through new contracts funded the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
- BARDA supports development of oral radiation drug [September 2011]
A drug that can be taken orally to treat internal contamination from radiation after a radiological attack will be developed under a new contract issued today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
- BARDA funds development of five drugs to protect against radiation [September 2011]
The development of five new drugs to treat injuries associated with acute radiation syndrome will move forward under contracts awarded by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
- 2010 Project BioShield Annual Report to Congress [July 2011]
During CY 2010, HHS used two of the Project BioShield authorities that require annual reporting: procurement of security countermeasures; and issuance of Emergency Use Authorizations
- BARDA Industry Day Contracting for Countermeasures, June 7-9, 2011 [June 2011]
BARDA Industry Day Contracting for Countermeasures
- BARDA supports first Project BioShield contract for smallpox drug Contract funds late-stage development, future acquisition of antiviral drug to treat smallpox [May 2011]
The Biomedical Advanced Research and Development Authority (BARDA) today announced a five-year, $433 million contract for late-stage development of an antiviral drug to treat individuals infected with smallpox
- Second Pre-Proposal Conference (RFP 11-SOL-00011), Centers for Innovation in Advanced Development and Manufacturing [May 2011]
Under RFP 11-SOL-00011, the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) and the Office of Acquisitions Management, Contracts & Grants (AMCG) seek to establish Centers for Innovation in Advanced Development and Manufacturing (the 'Centers') as public-private partnerships that share facility construction costs, facilitate medical countermeasure (MCM) product development, ensure domestic vaccine manufacturing surge capacity, and provide workforce development training programs
- BARDA funds development of drug to prevent radiation lung injury [May 2011]
The Biomedical Advanced Research and Development Authority (BARDA) today announced a two-year, $3.51 million contract with Humanetics Corp. of Eden Prairie, Minn., to develop a drug that may prevent lung injury caused by exposure to high levels of ionizing (damaging) radiation from a nuclear detonation
- HHS/BARDA Centers for Innovation in Advanced Development and Manufacturing Webinar [March 2011]
Event: HHS/BARDA Centers for Innovation in Advanced Development and Manufacturing
- BARDA funds advanced development of new influenza antiviral [March 2011]
A contract has been awarded to develop a long-acting single-dose antiviral drug for use in the United States, the U.S. Biomedical Advanced Research and Development Authority (BARDA) announced today
- BARDA supports development of drugs to protect against radiation [February 2011]
Two contracts for advanced development of drugs to treat skin and lung injuries associated with acute radiation syndrome (ARS) were awarded this week by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).
- BARDA supports next steps for a new antiviral drug for smallpox [February 2011]
The U.S. Department of Health and Human Services (HHS) awarded two contracts today to help make vaccine available more quickly for seasonal flu outbreaks and pandemics
- HHS awards contracts to develop new flu vaccine technology [February 2011]
The U.S. Department of Health and Human Services (HHS) awarded two contracts today to help make vaccine available more quickly for seasonal flu outbreaks and pandemics
2010
- Animal Model Draft Guidance Public Meeting, November 5, 2010 [November 2010]
Animal Model Draft Guidance Public Meeting, November 5, 2010
- BARDA funds year-round egg supply for pandemic flu vaccine [October 2010]
A $57 million three-year federal contract will secure a continued year-round supply of eggs and other essential supplies for pandemic influenza vaccine as part of pandemic preparedness
- BARDA funds development of new way to treat illness from acute radiation [September 2010]
BARDA funds development of new way to treat illness from acute radiation
- BARDA awards $51 million contract for next generation anthrax vaccine [September 2010]
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md.
- BARDA funds medical countermeasure innovation:Eight contracts for products and technology to protect Americans awarded for $55-$100 million [September 2010]
September 21, 2010: The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) announced the first eight contract awards under an initiative to help modernize and improve the nation's infrastructure for producing medical countermeasures that protect against natural and man-made biological threats
- BARDA funds development of next-generation portable ventilators [September 2010]
A $6.7 million contract announced today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) will help fill the need for domestically manufactured, low-cost, user-friendly and flexible next-generation ventilators
- BARDA grants help build international flu vaccine capacity [September 2010]
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) is providing three sets of grants totaling $10.4 million
- Review calls for new federal approach to medical countermeasures: HHS Secretary releases review and recommendations driven by pandemic flu experience [August 2010]
U.S. Department of Health and Human Services Secretary Kathleen Sebelius today released an examination of the federal government's system to produce medications, vaccines, equipment and supplies needed for a health emergency, known as medical countermeasures
- BARDA supports development of new drugs to treat radiation injury [August 2010]
The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA)
- BARDA funds drug development for biothreats, antibiotic resistance [August 2010]
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to develop an antibiotic that could be used against possible two types of bioterrorism as well as common infections that are becoming resistant to antibiotics
- ASPR Awards $54 Million to Support Making Anthrax Vaccine in U.S. [July 2010]
The U.S. Department of Health and Human Services' Assistant Secretary for Preparedness and Response today announced a $54 million multiple year contract with Emergent BioDefense Operations Lansing (EBOL), a subsidiary of Emergent BioSolutions Inc., to support the development of domestic manufacturing capacity for anthrax vaccine.
- First Smallpox Vaccine for Special Populations Delivered Under Project BioShield [July 2010]
Delivery to the Strategic National Stockpile of the first 1 million doses of the nation's first smallpox vaccine for certain immune-compromised populations is now complete, the result of a Project BioShield contract
- BARDA Awards Four Contracts for Innovative Platform Technologies Applied to Medical Countermeasure Development [July 2010]
The HHS Biomedical Advanced Research and Development Authority (BARDA) awarded four contracts for the advanced research and development of innovative platform technologies
2009
- NIH Prepares to Launch 2009 H1N1 Influenza Vaccine Trial in People with Asthma [December 2009]
The National Institutes of Health is preparing to launch the first government-sponsored clinical trial to determine what dose of the 2009 H1N1 influenza vaccine is needed to induce a protective immune response in people with asthma, especially those with severe disease.
- HHS Orders Intravenous Antiviral Flu Medication to Help Patients Hospitalized with 2009 H1N1 [December 2009]
The U.S. Department of Health and Human Services (HHS) today announced contract awards for up to 120,000 treatment courses of intravenous (IV) antiviral drugs to help treat hospitalized 2009 H1N1 influenza patients
- HHS awards contract to Bavarian Nordic For The Continued development of a freeze-dried formulation of the Imvamune (r) Smallpox Vaccine [December 2009]
On November 16, 2009, the Biomedical Advanced Research and Development Authority (BARDA) awarded an advanced research and development contract to Bavarian Nordic A/S of Copenhagen, Denmark
- HHS modifies approach to supporting second generation anthrax vaccine [December 2009]
The HHS Biomedical Research and Development Authority (BARDA) will cancel its request for proposal (RFP) for "Recombinant Protective Antigen Anthrax Vaccine for the Strategic National Stockpile" (RFP-BARDA-08-15).
- BARDA awards contracts for tests and devices to help the nation respond to a radiological emergency [December 2009]
The HHS Biomedical Advanced Research and Development Authority (BARDA) is awarding nine contracts for the advanced research and development of more effective tests and devices to determine the level of radiation a person has absorbed after a nuclear or radiological incident
- BARDA awards up to $143 million for advanced development of a new drug to treat anthrax [December 2009]
The HHS Biomedical Advanced Research and Development Authority (BARDA) today awarded a contract to Elusys Therapeutics, Inc. of Pine Brook, N.J., for the advanced development of a medication to treat inhalational anthrax, one of the top bioterrorism threats facing the nation
- Studies in Animals Suggest 2009 H1N1 Virus May Have Biological Advantage Over Seasonal Influenza Viruses [September 2009]
Preliminary findings in ferrets suggest that the novel 2009 H1N1 influenza virus may outcompete human seasonal influenza viruses, researchers say.
- Early Results: In Children, 2009 H1N1 Influenza Vaccine Works Like Seasonal Flu Vaccine [September 2009]
Early results from a trial testing a 2009 H1N1 influenza vaccine in children look promising
- Early Results from Clinical Trials of 2009 H1N1 Influenza Vaccines in Healthy Adults [September 2009]
We are encouraged by reports that are now emerging from various clinical trials of 2009 H1N1 influenza vaccines, conducted by various vaccine manufacturers. We expect additional companies to announce their preliminary trial results shortly
- NIAID Launches 2009 H1N1 Influenza Vaccine Trial in Pregnant Women [September 2009]
The first trial testing a candidate 2009 H1N1 influenza vaccine in pregnant women is launching this week, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today
- Award: A New Contract for the Purchase of Vaccine against the H1N1 2009 Variant Influenza Virus [August 2009]
A new contract for the purchase of vaccine against the H1N1 2009 variant influenza virus
- Synopsis: BARDA-RFP-09-101: R&D for Satisfactory Method of Pediatric Prussian Blue (Radiogardase) [August 2009]
The Government intends to award a sole source contract under the authority of FAR Part 6.302-1 to the Heyltex Corporation for the performance of research and development (R&D) to develop a satisfactory method of administering Radiogardase® (Prussian blue) to pediatric subjects (age 0-2)
- RFA-AI-09-027: Partnerships for Biodefense Food- and Water-borne Diseases [July 2009]
Part I Overview Information
- The White House Announces H1N1 Flu Preparedness Summit [July 2009]
MEDIA ADVISORY: The White House Announces H1N1 Flu Preparedness Summit
- Online Course: Emergency Use Authorization [July 2009]
Welcome to EMERGENCY USE AUTHORIZATION An online course developed by the Food and Drug Administration and Centers for Disease Control and Prevention.
- Amendment: BARDA-BAA-09-100-SOL-00010: Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development [July 2009]
HHSO100201100046C / Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development - BARDA-BAA-09-100-SOL-00010
- Video: 2009 Flu Summit [July 2009]
Information and video from the July 9, 2009 H1N1 Flu Preparedness Summit held at the National Institutes of Health in Bethesda, Maryland is now available.
- Synopsis: SS-BARDA-09-39: Laboratory Testing Services [July 2009]
This Sources Sought Notice (SSN) is not a Request for Proposal (RFP) and does not constitute a commitment by the Government.
- New Requirement: BAA-BARDA-09-34: solutions being sought via call for white papers for treatment of cutaneous and/or pulmonary injuries resulting from exposure to ionizing radiation [July 2009]
BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures
- New Videos: CBRN Medical Countermeasures Workshop 2009 [July 2009]
The Office of the Biomedical Advanced Research and Development Authority Divisions of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures and Acquisitions Management Systems (AMS) hosted workshop for stakeholders in industry and academia.
- Amendment 2: HHS-BARDA-09-32: Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness [July 2009]
Advanced Development of Recombinant Influenza Vaccine Products and Manufacturing Capabilities for Pandemic Preparedness.
- Synopsis: HHSO100200900109C: Novel Strategies for Situational Awareness of Healthcare System Functioning and Capacity: A Focus on H1N1 (s-OIV) [July 2009]
The Department of Health and Human Services, Assistant Secretary for Preparedness and Response, Office of Preparedness and Emergency Operations (OPEO) intends to enter into a noncompetitive contract with the Center for Biosecurity at the University of Pittsburgh Medical Center (UPMC).
- HHS 2009 H1N1 Vaccine Development Activities [June 2009]
The newly emergent 2009 H1N1 influenza virus is a novel virus with pandemic potential.
- 2009-H1N1 Influenza Vaccine Development Next Steps: Questions and Answers [June 2009]
2009-H1N1 Influenza Vaccine Development Next Steps: Questions and Answers
- Synopsis: BARDA-BAA-09-100-SOL-00010: Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development [June 2009]
Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development
- Synopsis: RFI-BARDA-09-38: Generating and Stockpiling Hyperimmune Plasma Against Botulinum Neurotoxin [June 2009]
Generating and Stockpiling Hyperimmune Plasma Against Botulinum Neurotoxin
- Justification and Approval: HHSO100200800071I: Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential [June 2009]
Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential
- Justification and Approval (J&A): HHSO100200800072I: Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential [June 2009]
Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential
- Justification and Approval (J&A): HHSO100200800073I: Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential [June 2009]
Modification of existing contracts to include purchase of (H1N1) influenza vaccine with pandemic potential
- Justification and Approval (J&A): HHSO100200900001I: A new contract for the purchase of vaccine against the H1N1 2009 variant influenza virus [June 2009]
A new contract for the purchase of vaccine against the H1N1 2009 variant influenza virus.
- Justification and Approval (J&A): HHSO100200900002I: A new contract for the purchase of vaccine against the H1N1 2009 variant influenza virus [June 2009]
A new contract for the purchase of vaccine against the H1N1 2009 variant influenza virus
- Presolicitation Notice: 09-100-SOL-00009: Independent Third Party Performance Testing for Advanced Development of Next Generation Portable Ventilators [June 2009]
Independent Third Party Performance Testing for Advanced Development of Next Generation Portable Ventilators
- Award: DHHS-BARDA-07-06: Advanced Development of Recombinant Influenza Virus Vaccines [June 2009]
65 -- Advanced Development of Recombinant Influenza Virus Vaccines
- PA-09-179: Development of In-Vitro Assays to Assess the Potency of Botulinum Neurotoxin Type A [May 2009]
Part I Overview Information
- Interim Guidance on Antiviral Recommendations for Patients with Novel Influenza A (H1N1) Virus Infection and Their Close Contacts [May 2009]
Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season
- CDC H1N1 Flu Update: U.S. Human Cases of H1N1 Flu Infection [May 2009]
2009 H1N1 Flu: Situation Update
- HHS 2009 H1N1 Vaccine Development Activities [May 2009]
The newly emergent 2009 H1N1 influenza virus is a novel virus with pandemic potential.
- 2009-H1N1 Influenza Vaccine Development Next Steps: Questions and Answers [May 2009]
2009-H1N1 Influenza Vaccine Development Next Steps: Questions and Answers
- U.S. 2009-H1N1 Vaccine Strategy [May 2009]
PDF: U.S. 2009-H1N1 Vaccine Strategy
- Amendment 3 to BAA-BARDA-09-36: Point of Care or High-Throughput Biological Assays for Determining Absorbed Ionizing Radiation Dose (Biodosimetry) after Radiologic and Nuclear Events [May 2009]
POINT OF CARE OR HIGH-THROUGHPUT BIOLOGICAL ASSAYS FOR DETERMINING ABSORBED IONIZING RADIATION DOSE (BIODOSIMETRY) AFTER RADIOLOGIC AND NUCLEAR EVENTS
- GAO Report: Influenza Pandemic: Sustaining Focus on the Nation's Planning and Preparedness Efforts [April 2009]
Sustaining Focus on the Nation's Planning and Preparedness Efforts
- Sources Sought: 09-100-SOL-00009: Independent Third Party Performance Testing for Advanced Development of Next Generation Portable Ventilators [April 2009]
Independent Third Party Performance Testing for Advanced Development of Next Generation Portable Ventilators
- Swine Flu: Emergency Use Authorization (EUA) of Medical Products and Devices [April 2009]
Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices
- Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts [April 2009]
Updated Interim Recommendations for the Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009-2010 Season
- WHO Elevates Pandemic Alert Level to Phase 5 [April 2009]
Based on assessment of all available information, and following several expert consultations, I have decided to raise the current level of influenza pandemic alert from phase 4 to phase 5.
- BAA-BARDA-09-34: BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures [March 2009]
BARDA Broad Agency Announcement for the Advanced Research and Development of Chemical, Biological, Radiological, and Nuclear Medical Countermeasures
- Avian Influenza Risk Perception among Poultry Workers, Nigeria [March 2009]
In Nigeria and other African countries, outbreaks caused by the Asian strain of highly pathogenic avian influenza virus (HPAI) subtype H5N1 have occurred in poultry.
- Scientists Identify Lab-Made Proteins That Neutralize Multiple Strains of Seasonal and Pandemic Flu Viruses [March 2009]
Scientists Identify Lab-Made Proteins That Neutralize Multiple Strains of Seasonal and Pandemic Flu Viruses
- Antibodies Neutralize Multiple Flu Strains [March 2009]
Antibodies Neutralize Multiple Flu Strains
- GAO Report: Influenza Pandemic: Sustaining Focus on the Nation's Planning and Preparedness Efforts [March 2009]
Influenza Pandemic: Sustaining Focus on the Nation's Planning and Preparedness Efforts
- Applications for $1.5 Billion in Recovery Act Funds Now Available (NIH) [March 2009]
Grants from National Institutes of Health Will Support Science and Research, Help Grow the Economy
- Solicitation: RFP-BARDA-09-35: Smallpox Anitiviral for the Strategic National Stockpile [March 2009]
SMALLPOX ANTIVIRAL FOR THE STRATEGIC NATIONAL STOCKPILE
- Solicitation: BARDA-09-100-SOL-00005: Advanced Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation [March 2009]
Advanced Therapeutics for Treating Neutropenia Resulting from Acute Exposure to Ionizing Radiation
- Synopsis: RFP-BARDA-09-35: Smallpox Antiviral for the Strategic National Stockpile [February 2009]
SMALLPOX ANTIVIRAL FOR THE STRATEGIC NATIONAL STOCKPILE
- Draft RFP HHS-BARDA-09-33: Advanced Development of Therapeutics for Neutropenia Resulting from Acute Exposure to Ionizing Radiation [February 2009]
Advanced Development of Therapeutics for Neutropenia Resulting from Acute Exposure to Ionizing Radiation
- Draft Guidance for Industry on Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic; Availability [January 2009]
Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During an Influenza Pandemic
- RFP-HHS-BARDA-08-09: Building Domestic Cell-Based Influenza Vaccine Manufacturing Facilities [January 2009]
Building Domestic Cell-Based Influenza Vaccine Manufacturing Facilities
- HHS Awards $487 Million Contract to Build First U.S. Manufacturing Facility for Cell-Based Influenza Vaccine [January 2009]
HHS Awards $487 Million Contract to Build First U.S. Manufacturing Facility for Cell-Based Influenza Vaccine
- Use of Protective Gear in Bird Flu Outbreak Response [January 2009]
CDC's Dr. Oliver Morgan discusses how the use of masks and other protective gear impacted whether workers dealing with an outbreak of bird flu in England became sick.
- Assessment of States' Operating Plans to Combat Pandemic Influenza [January 2009]
A pandemic occurs in many localities - perhaps even worldwide - almost simultaneously. Because of this, much of the planning for a pandemic must be the responsibility of state and local governments.
- Pandemic Planning Update VI [January 2009]
Pandemic Planning Update VI
- Public Health Preparedness: Strengthening CDC's Emergency Response [January 2009]
Public Health Preparedness: Strengthening CDC's Emergency Response
2008
- PreSol-HHS-BARDA-08-20: Advanced Development of Next Generation Portable Ventilators [December 2008]
Advanced Development of Next Generation Portable Ventilators
- WHO: Avian Influenza - situation in Egypt [December 2008]
16 December 2008 -The Ministry of Health and Population of Egypt has announced a new human case of avian influenza A(H5N1) virus infection.
- HHS Releases Guidance for Use and Stockpiling of Antiviral Drugs for Pandemic Influenza [December 2008]
Health care workers and emergency services personnel who could have direct contact with individuals who are ill during an influenza pandemic should be protected with antiviral drugs throughout the pandemic, even before these workers are exposed or become ill themselves, according to guidance released today by the U.S. Department of Health and Human Services.
- Importance of Influenza Vaccination for Health Care Personnel [November 2008]
With the annual influenza season underway, the Food and Drug Administration (FDA) is urging health care organizations to ensure that influenza vaccination programs are available for health care personnel (HCP).
- Secretary Leavitt's Pandemic Planning and Preparedness Webcast [November 2008]
Secretary Leavitt's Pandemic Planning and Preparedness Webcast
- Award: Anthrax Vaccine Adsorbed for the Strategic National Stockpile (SNS) [October 2008]
Anthrax Vaccine Adsorbed for the Strategic National Stockpile (SNS)
- FDA Issues Emergency Use Authorization to Protect Postal Workers to help protect postal workers from an anthrax attack [October 2008]
Federal Register / Vol. 73, No. 194 / Monday, October 6, 2008 / Notices
- NIAID Scientists to Speak on Range of Infectious Disease Topics at Major Scientific Meeting [October 2008]
NIAID Scientists to Speak on Range of Infectious Disease Topics at Major Scientific Meeting
- SS-BARDA-09-Serology: Immunological Testing of Sera Samples [October 2008]
Immunological Testing of Sera Samples
- Building Domestic Cell-Based Influenza Vaccine Manufacturing Facilities [September 2008]
The Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA) requires the services of a contractor(s) to design, construct, validate and perform regulatory activities.
- Acquisition of Avian Influenza H5N1 Vaccine for Strategic National Stockpile [September 2008]
The Department of Health and Human Services has a requirement for the acquisition of avian influenza H5N1 vaccine for the Strategic National Stockpile (SNS).
- Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss and Vascular Injury Resulting From Acute Exposure to Ionizing Radiation [September 2008]
Therapies for Hematopoietic Syndrome, Bone Marrow Stromal Cell Loss and Vascular Injury Resulting From Acute Exposure to Ionizing Radiation
- Advanced Development of Next Generation Portable Ventilators [September 2008]
Advanced Development of Next Generation Portable Ventilators
- RFP-BARDA-08-28: Advanced Development of New Antiviral Agents against Influenza Virus [September 2008]
Advanced Development of New Antiviral Agents against Influenza Virus
- Bacterial Pneumonia and Pandemic Influenza Planning [August 2008]
Pandemic influenza planning is well under way across the globe. Antiviral drugs and vaccines have dominated the therapeutic agenda. Far less work has been conducted on stockpiling and planning for deployment of antimicrobial drugs against secondary bacterial pneumonia, a cause of substantial illness and death in previous pandemics and epidemics.
- HHS and DHS Announce Guidance on Pandemic Vaccination Allocation [August 2008]
The U.S. Departments of Health and Human Services (HHS) and Homeland Security (DHS) released today guidance on allocating and targeting pandemic influenza vaccine.
- Public Workshop: Animal Models for the Treatment of Acute Radiation Syndrome [August 2008]
The purpose of the public workshop is to discuss issues that should be considered when developing animal models to assist in developing and demonstrating the efficacy of products intended for treatment of ARS.
- HHS Purchases 45,000 Additional Courses Anthrax Antitoxin Under Project BioShield [July 2008]
The Department of Health and Human Services (HHS) announced today that it contracted to purchase 45,000 new treatment courses of ABthrax, an anthrax therapeutic treatment, from Human Genome Sciences of Rockville, MD for $150,000,000.
Back to Top
